Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Halozyme Therapeutics
Pharma
FDA approves BMS' subcutaneous Opdivo with some limitations
The subcutaneous approval covers nearly all existing solid tumor indications for intravenous Opdivo with the exception of its combo uses with Yervoy.
Angus Liu
Jan 2, 2025 9:15am
Argenx adds 4 new targets to Halozyme collab for $30M
Oct 3, 2024 10:54am
Roche's subcutaneous Tecentriq wins FDA nod after delay
Sep 13, 2024 11:41am
Arbitrator sides with J&J, upholding Darzalex ruling vs. Genmab
Jan 23, 2024 10:23am
BMS's subcutaneous Opdivo measures up to infused version
Oct 19, 2023 11:10am
Roche scores with subcutaneous version of MS drug Ocrevus
Jul 13, 2023 10:18am
